Share on StockTwits
 

Gilead Sciences (NASDAQ:GILD)’s share price reached a new 52-week high during trading on Thursday, Analyst Ratings News reports. The stock traded as high as $79.02 and last traded at $77.39, with a volume of 15,397,454 shares traded. The stock had previously closed at $75.23.

Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “positive” rating on shares of Gilead Sciences in a research note to investors on Wednesday. Separately, analysts at Nomura initiated coverage on shares of Gilead Sciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, January 6th. They now have a $102.00 price target on the stock, up previously from $80.00. Two equities research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $79.76.

Gilead Sciences has a one year low of $38.27 and a one year high of $76.11. The stock’s 50-day moving average is $73.66 and its 200-day moving average is $65.38. The company has a market cap of $118.7 billion and a P/E ratio of 41.40.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.